Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + nab-paclitaxel + cisplatin
- Development stage
- Phase 4
- Lead developer
- Sun Yat-sen University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This combination therapy is a chemoimmunotherapy regimen being investigated by Sun Yat-sen University for the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC), specifically cases with skull base invasion. The regimen consists of **tislelizumab**, a humanized IgG4 monoclonal antibody designed to bind to the programmed cell death protein 1 (PD-1) receptor and inhibit its interaction with PD-L1 and PD-L2; **nab-paclitaxel** (nanoparticle albumin-bound paclitaxel), a microtubule inhibitor; and **cisplatin**, a platinum-based DNA alkylating agent. In the clinical trial setting, this combination is utilized as a neoadjuvant therapy to reduce tumor volume and improve surgical resectability, followed by surgery, (chemo)radiotherapy, and adjuvant tislelizumab monotherapy. The approach aims to exploit the synergistic potential of cytotoxic chemotherapy and immune checkpoint inhibition to enhance pathological response rates and long-term survival in high-risk HNSCC patients.
- Other names
- tislelizumab + albumin-bound paclitaxel + cisplatintislelizumab + nab-paclitaxel + cisplatin regimen
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on tislelizumab + nab-paclitaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + nab-paclitaxel + cisplatin.